<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166517">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01940198</url>
  </required_header>
  <id_info>
    <org_study_id>AI424-417 ST</org_study_id>
    <nct_id>NCT01940198</nct_id>
  </id_info>
  <brief_title>Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia</brief_title>
  <acronym>REfLecT</acronym>
  <official_title>Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holdsworth House Medical Practice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Holdsworth House Medical Practice</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study will aim to determine long-term atazanavir experience in a high HIV
      caseload primary care practice in Sydney, Australia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This observational study will aim to determine long term atazanavir experience in HIV-1
      infected patients in a primary care setting.

      3. OBJECTIVES OF THE STUDY i. Primary objective Long-term (2 years or greater) atazanavir
      experience in HIV-1 infected patients in a primary care setting through retrospective data
      collection.

      ii. Secondary objectives

        1. To illustrate long term therapeutic efficacy of atazanavir in ART na誰ve and experienced
           HIV-1 infected patients.

        2. To illustrate long term tolerability to atazanavir in ART na誰ve and experienced HIV-1
           infected patients.

        3. To identify ART treatment history in ART na誰ve and experienced HIV-1 infected patients
           on ATV.

        4. To identify contraindicated therapy in ART na誰ve and experienced HIV-1 infected
           patients on ATV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Proportion of HIV-1 infected participants with atazanavir experience</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients who continue on atazanavir for 2 years or greater from baseline to termination/current.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of HIV-1 infected participants with atazanavir experience</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>1.	Therapeutic efficacy of atazanavir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of HIV-1 infected participants with atazanavir experience</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tolerability to atazanavir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of HIV-1 infected participants with atazanavir experience</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>ART treatment history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of HIV-1 infected participants with atazanavir experience</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>contraindicated therapy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">117</enrollment>
  <condition>HIV</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of HIV-1 positive patients attending Holdsworth House Medical Practice who have
        commenced ATV as a component of ART will be identified from review of current database.

        Data will be collected retrospectively from patient electronic medical records for HIV-1
        positive patients that have commenced ATV from year 2002 - 2008.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 positive

          2. Have commenced ATV between 2002-2008 (Baseline)

          3. Follow-up data (clinical and laboratory) available from baseline

        Exclusion Criteria:

          1. Patients not commenced ATV between 2002-2008

          2. No follow-up data (clinical and laboratory) available from baseline

          3. Patient 'lost to follow-up' with &lt; 2 years of follow-up data (Clinical and
             laboratory)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Bloch, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holdsworth House Medical Practice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 8, 2013</lastchanged_date>
  <firstreceived_date>June 1, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Holdsworth House Medical Practice</investigator_affiliation>
    <investigator_full_name>Dr. Mark Bloch</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Atazanavir</keyword>
  <keyword>long-term</keyword>
  <keyword>primary care setting</keyword>
  <keyword>sydney</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atazanavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
